Introduction {#s1}
============

Her2 (also known as Neu or ErbB2), a receptor tyrosine kinase belonging to the human epidermal growth factor receptor (EGFR) family that also includes EGFR/Her1, Her3, and Her4, is an important component of cell-signaling networks, and is implicated in the growth of a variety of cancers ([@bib23]; [@bib36]; [@bib4]; [@bib28]). The receptors of the EGFR family activate through dimerization ([Figure 1A](#fig1){ref-type="fig"}), which is promoted by the binding of ligands from the EGF family ([@bib43]; [@bib37]; [@bib9]) to the receptors' extracellular regions ('ectodomains'). This activation process relies on a number of allosteric interactions in the extracellular, transmembrane, and intracellular portions of the receptor ([@bib14], [@bib13]; [@bib3]), which lead to the formation of a specific asymmetric active dimer of the intracellular kinase domains ([@bib44]). Her2 is unique in the family in that it does not homodimerize under normal conditions, and its ectodomain does not bind ligands. Instead, it activates through heterodimerization with other members of the family (EGFR and Her3, in particular) when they are bound to ligands ([@bib11]; [@bib4]).10.7554/eLife.00708.003Figure 1.Receptors of the human EGFR family and conformations of their ectodomains.(**A**) Left: the four members of the human EGFR family, each consisting of an ectodomain, a single-pass transmembrane helix, and an intracellular module that includes a kinase domain. As shown, Her2 bears a closed ligand binding site and does not bind EGF-like ligands. Her3 is kinase-dead, and its intracellular module is thus colored gray. Right: common homo- and heterodimers of the EGFR family. The Her2 homodimer is rendered semitransparent to indicate its instability in normal cell conditions. (**B**) Schematic of the ligand-free Her2 ectodomain monomer, as observed crystallographically (PDB entries 1N8Z, 2A91, 1S78, 3N85, and 3MZW). Domain II is bent. (**C**) Schematic of the crystal structure of the 2-ligand EGFR ectodomain dimer (PDB entry 1NJP). The dimer is symmetric, and domain II is straight in both subunits. (**D**) Schematic of the crystal structure of the dEGFR ectodomain dimer (PDB entry 3LTF). Although Spitz ligands are bound to both subunits, the structure is asymmetric; domain II is straight in one subunit but bent in the other. Domain V and part of domain IV were not resolved in this crystal structure and are not shown in the schematic. The conformations of the bent and straight domain IIs in (**B**), (**C**), and (**D**) are indicated by the black lines.**DOI:** [http://dx.doi.org/10.7554/eLife.00708.003](10.7554/eLife.00708.003)

The complexity of signaling underpinned by homo- and heterodimerization of EGFR family members emerged relatively recently in evolution. EGFR families in invertebrates have only one member, but gene duplication gave rise to two-member EGFR families in early vertebrate species, such as fishes. Further gene duplication eventually generated the four members of the mammalian EGFR family ([@bib40]). The increase in the number of EGFR family members, accompanied by increasing diversity of the extracellular ligands they interact with, gave rise to a complex signaling network: homo- and heterodimerization of various EGF receptors, induced by ligand binding, began to generate a variety of unique signaling outputs controlled by the identity of the bound ligands.

The unique dimerization properties of Her2 are believed to be essential to its critical role as a potent signal amplifier for the other receptors of the EGFR family. The Her3--Her2 heterodimer is particularly prevalent and potent in signaling. The prominence of Her3--Her2 heterodimers is particularly intriguing, since Her2 itself lacks an activating ligand and Her3 is impaired in its kinase activity ([Figure 1A](#fig1){ref-type="fig"}). These receptors act primarily through heterodimerization. The unique partnership of Her2 and Her3 has been aptly dubbed 'the deaf and the dumb' ([@bib10]). By activating several downstream pathways, including those of MAPK, PI3K, phospholipase C, protein kinase C, and Janus kinase, the Her3--Her2 heterodimer plays a pivotal role in the determination of cell lineage in a variety of tissues in epithelial organs. Experiments have shown that knocking out Her2 and Her3 genes leads to defective development of the heart, mammary gland, and nervous system in mice phenotypes. It is thus not surprising that Her3--Her2 heterodimers are implicated in a number of forms of cancer ([@bib10]) or that Her2 is an important drug target in cancer therapeutics.

The structural mechanism underlying Her2's dimerization properties remains incompletely understood. In particular, the conformations of Her2 homo- and heterodimers remain obscure, and how these conformations relate to the dimerization affinities is uncertain. Moreover, the manner in which ligands binding to Her2's heterodimerization partners regulate the conformations and stability of the heterodimers is poorly understood. Although various structural and electrostatic factors that may affect Her2 dimerization have been discussed in the literature ([@bib8]; [@bib17]; [@bib19]; [@bib1], [@bib2]; [@bib30]), further structural elucidation is needed for a better molecular understanding of Her2 activation.

Crystal structures of the ectodomains of human EGFR-family receptors ([@bib27]) provide a starting point for elucidation of the structural mechanisms of Her2 heterodimerization. In these structures ([Figure 1B,C](#fig1){ref-type="fig"}), the ectodomains (each consisting of four domains numbered I, II, III, and IV) are found either as monomers or as symmetric homodimers with ligands bound to both dimer subunits ([@bib18]; [@bib31]; [@bib34]; [@bib30]). In the homodimer structures, domain II constitutes most of the ectodomain's dimer interface ([Figure 1C](#fig1){ref-type="fig"}), and its conformation is critical to ectodomain dimerization. A bent domain II is found in all ligand-free, inactive ectodomains of the EGFR-family receptors ([Figure 1B](#fig1){ref-type="fig"}), while a straight domain II is associated with the (ligand-bound) active dimer ([Figure 1C](#fig1){ref-type="fig"}). The domain II of Her2 appears to be constitutively bent ([@bib8]; [@bib19]; [@bib17]; [@bib1]), which is consistent with its poor homodimerization. Unfortunately, no crystal structure is available for human EGFR family heterodimers with only a single ligand bound, as is the case for Her2 heterodimers.

Intriguingly, recent crystal structures of *Drosophila* EGFR (dEGFR) ectodomains reveal asymmetric dimers that bear only one fully formed ligand binding site, with the other partially closed, regardless of whether one or both subunits are ligand-bound ([@bib1], [@bib2]). These dEGFR structures hint at a possible structural mechanism for Her2 heterodimerization, but translating the dEGFR results to human Her2 is difficult due to differences between these receptors. First, dEGFR dimers assume an asymmetric conformation even when ligands are bound to both dimer subunits, whereas all existing human EGFR-family dimer structures exhibit a symmetric conformation. Second, the ectodomains of Her2 and other members of the human EGFR family each comprise four domains, whereas the dEGFR ectodomain includes a fifth domain, consisting of 166 residues immediately N-terminal to the transmembrane helix.

Here we investigate the dimerization of Her2 using molecular modeling and long-timescale molecular dynamics (MD) simulations. We modeled and simulated the EGFR--Her2 and Her3--Her2 heterodimers as well as the Her2 homodimer. The heterodimers were found to be stable when a ligand was bound to the EGFR or Her3 subunit. Our simulations further showed that, when the single bound ligand was removed from a Her2 heterodimer, a substantial gap developed in the dimer interface. A similar gap was also observed in our simulation of the Her2 homodimer, which explains the weak homodimerization of Her2. Structural analysis shows that such a gap arises from the bending of the domain IIs in both subunits due to the absence of bound ligands. These observations are strikingly similar to the findings from the crystal structures of dEGFR homodimers ([@bib1], [@bib2]): the ligand-free, but not the ligand-bound, dEGFR dimer exhibits a gap in the dimer interface, which explains the reduced dEGFR dimerization in the absence of ligands. In agreement with the recent experimental data showing that a single bound ligand is sufficient to activate an EGFR dimer ([@bib30]), our simulations demonstrate that the activation mechanism of the receptors of the human EGFR family and of Her2 in particular conserves *Drosophila* EGFR's capacity to form stable asymmetric ectodomain dimers upon the binding of a single ligand.

Results {#s2}
=======

Simulations reproduce the gap in the interface of the dEGFR dimer {#s2-1}
-----------------------------------------------------------------

The general approach of this study was to use long-timescale MD simulations to infer from crystal structures of EGFR ectodomain dimers the structures of dimers with different constituent receptors or with different bound ligands. To examine the validity of this approach, we first applied it to dEGFR, for which the structures of both the ligand-bound and ligand-free ectodomain dimers ([@bib1], [@bib2]) have been resolved. Our simulations correctly demonstrated that, once the ligands are removed from the ligand-bound structure, a substantial gap between the two subunits develops, leading to a reduced dimerization interface.

Unlike the symmetric human '2-ligand' EGFR dimer (in which both subunits bear fully formed and occupied ligand binding sites; [Figure 1C](#fig1){ref-type="fig"}), the 2-ligand dEGFR dimer is asymmetric: although both ectodomain subunits are ligand-bound, only one bears a fully formed ligand binding site and a straight domain II ([Figure 2A](#fig2){ref-type="fig"}). The '1-ligand' dEGFR dimer (in which only one subunit is ligand-bound) is essentially identical to the 2-ligand dimer, except for the missing ligand. The gap between the two subunits is closed in both dEGFR dimers. Conversely, the ligand-free dEGFR dimer is symmetric, featuring a bent domain II in both subunits, and a gap in the dimer interface. We removed both ligands from the crystal structure of the 2-ligand dEGFR dimer (PDB entry 3LTF) and simulated the resulting system. In two independent simulations, a substantial gap emerged in the dimer interface, and the resulting conformation resembled that of ligand-free dEGFR crystal structures ([Figure 2A,B](#fig2){ref-type="fig"}). [Figure 2C](#fig2){ref-type="fig"} shows a significant reduction in the surface area buried within the dimer interface, consistent with the buried areas in the crystal structures of the ligand-free dEGFR dimers. We note that the dimer conformation drifted away from that of the ligand-free crystal structure after ∼2 µs. This reflected the high flexibility of the simulated dimer, likely a result of the truncation of the domain IVs in the resolved crystal structure from which the simulations were initiated and the lack of inter-subunit contact between the two domains. The fact that our dEGFR simulations were able to reproduce the gap in the dimer interface found in the crystal structures of ligand-free dEGFR dimers lends support to the approach we adopted for the analysis of Her2 dimerization.10.7554/eLife.00708.004Figure 2.Simulations reproduce the gap in the interface of the dEGFR ectodomain dimer.(**A**) The schematic shows the 2-ligand dEGFR ectodomain dimer on the left. In simulations initiated from this structure with both ligands removed, gap opened in the dimer interface, as indicated by a V-shaped outline in the right diagram. In the ligand-free dimer, domain II is bent in both subunits. The simulation snapshots are shown below the schematic diagrams. (**B**) The simulated dEGFR dimer from (**A**), at *t* = 0.5 µs, is compared with the crystal structure of the ligand-free dEGFR dimer (tan). Molecular renderings (**A**, **B**) omit domains IV and V for clarity (although the crystallographically resolved portion of domain IV was present in simulations). (**C**) The surface area buried within the dimer interface (counting the contributions from domains I, II, and III). The results of three independent simulations are shown, two starting from the 2-ligand crystal structures (after removal of the ligands), and one from the ligand-free crystal structure.**DOI:** [http://dx.doi.org/10.7554/eLife.00708.004](10.7554/eLife.00708.004)

Models of the EGFR--Her2 heterodimer and Her2 homodimer {#s2-2}
-------------------------------------------------------

The 2-ligand EGFR homodimer has been resolved crystallographically ([@bib18]; [@bib34]; [@bib31]) and studied previously using MD simulations (e.g., [@bib42]; [@bib45]). Given the close homology between the EGFR-family receptors ('Materials and methods'), this crystal structure may serve as a starting point for the modeling of Her2 homo- and heterodimers.

The first model we constructed was that of the ligand-bound EGFR--Her2 heterodimer, in which the EGFR subunit is ligand-bound and the Her2 subunit is ligand-free. We assumed that a 1-ligand EGFR homodimer is structurally similar to this EGFR--Her2 heterodimer and thus may serve as a template. To obtain a structure of the 1-ligand EGFR homodimer, we removed one ligand from the crystal structure of the 2-ligand EGFR homodimer (PDB entry 3NJP \[[@bib31]\]) and simulated the remaining complex ([Figure 3A](#fig3){ref-type="fig"}). In all three independent simulations performed, the dimer assumed an asymmetric conformation, in which the ligand-free subunit differs from the ligand-bound one. In the former, the space previously occupied by the bound ligand between domains I and III is closed and domain II is bent ([Figure 3B](#fig3){ref-type="fig"}), in agreement with a recent MD study ([@bib42]). It is notable that the removal of one of the two ligands from the ectodomain dimer did not lead to substantial decrease in the area of the dimer interfaces ([Figure 3E](#fig3){ref-type="fig"}), suggesting that, in agreement with recent experimental findings ([@bib30]), a single bound ligand is sufficient to maintain a stable ectodomain dimer of EGFR. By comparison, no significant conformational changes were observed in the control simulations of the 2-ligand EGFR dimer.10.7554/eLife.00708.005Figure 3.Bending of domain II.(**A**) A schematic showing how the model of the 1-ligand EGFR dimer (right) is generated by simulation after the removal of one EGF ligand from the crystal structure of the 2-ligand dimer (left). The resulting structure is asymmetric: domain II of the ligand-free subunit is bent and the binding site is closed, whereas domain II of the ligand-bound subunit is straight and the binding site is open (as is the case in both subunits of the 2-ligand dimer). The angle *θ*, which characterizes the bending of domain II, is measured between the Cα atoms of EGFR residues 194, 239, and 296. (**B**) Bending of domain II. A simulation snapshot of the ligand-free subunit (red) from the 1-ligand EGFR dimer is overlaid with the crystal structures of a subunit from the 2-ligand EGFR dimer (green). EGFR residues 240--309 are used for reference. (**C**) An overlay of the ligand-free subunit of the 1-ligand EGFR dimer, generated by simulation (red), with the crystal structure of Her2 monomer (cyan). In the interest of clarity, domain IV is not shown. (**D**) The angle *θ* (illustrated in \[**A**\]) is shown as function of time in the three independent simulations of the 1-ligand EGFR homodimer, for the ligand-free subunit (middle) and for the ligand-bound subunit (right). The value of *θ* in the crystal structure of Her2 monomer is indicated by a straight line. (**E**) The buried surface area at the interfaces of 1-ligand and 2-ligand EGFR dimers in simulation.**DOI:** [http://dx.doi.org/10.7554/eLife.00708.005](10.7554/eLife.00708.005)

The conformation of the ligand-free subunit in the simulated 1-ligand EGFR homodimer resembles the crystal structure of Her2 monomer ([Figure 3C](#fig3){ref-type="fig"}), especially in the bending of domain II. (The bent domain II is also observed in the crystal structures of ligand-free EGFR monomers \[PDB entries 1NQL and 1YY9; [@bib15]; [@bib29]\].) The bending in domain II can be characterized by the angle *θ* formed by the top, middle, and bottom regions of the domain II dimerization interface ([Figure 3A,D](#fig3){ref-type="fig"}). In our simulations, this angle was ∼150° to 160° in the ligand-free subunits and ∼170° in the ligand-bound subunits, with the former values being very close to that of the Her2 crystal structure (156°). The EGFR--Her2 heterodimer was thus modeled by superimposing a crystal structure of the monomeric Her2 ectodomain (PDB entry 3BE1 \[[@bib6]\]) onto the ligand-free EGFR subunit in the 1-ligand EGFR dimer using the portion of domain II directly involved in dimerization (EGFR residues 240--309; see 'Materials and methods').

We subsequently modeled the ligand-free EGFR--Her2 heterodimer and the Her2 homodimer using a similar approach. In the former case, the ligand was removed from our model of the EGFR--Her2 heterodimer and the resulting ligand-free heterodimer was then simulated. In the simulations, domains I, II, and III of the EGFR subunit again assumed a 'Her2-like'conformation. This model of the ligand-free EGFR--Her2 heterodimer was then used as a template for the Her2 homodimer, in the same way that the model of the 1-ligand EGFR homodimer was used as a template for the EGFR--Her2 heterodimer ('Materials and methods').

Dynamics of the dimer interfaces in the EGFR--Her2 heterodimer and Her2 homodimer {#s2-3}
---------------------------------------------------------------------------------

We subsequently simulated the EGFR--Her2 heterodimer and Her2 homodimer starting from these models. In these simulations, the ligand-bound EGFR--Her2 heterodimer remained stable ([Figure 4A](#fig4){ref-type="fig"}), the dimer interface was largely intact, and the ligand wedged between domains I and III of the EGFR subunit, preventing any bending in this subunit's domain II. In contrast, a large gap opened in the dimer interface of the ligand-free EGFR--Her2 heterodimer (this was consistently observed in two independent simulations) between the N-terminal portions of the domain IIs ([Figure 4B](#fig4){ref-type="fig"}; [Video 1](#video1){ref-type="other"}). This occurred as domain II of the EGFR subunit bent away from the dimer interface upon the removal of its bound ligand. Similarly, a gap at the dimer interface was also observed in two independent simulations of the Her2 homodimer ([Figure 4C](#fig4){ref-type="fig"}). Plots of the buried surface area show that the size of the gap fluctuated in the simulations ([Figure 4B](#fig4){ref-type="fig"}), but on average, was significantly lower in the ligand-free EGFR--Her2 heterodimer and Her2 homodimer than in the ligand-bound heterodimer.10.7554/eLife.00708.006Figure 4.Simulations of the EGFR--Her2 heterodimer and the Her2 homodimer.(**A**) The EGFR--Her2 heterodimer with the ligand bound to EGFR ('+EGF'). (**B**) The ligand-free EGFR--Her2 heterodimer or EGFR--EGFR homodimer ('−EGF'). (**C**) The Her2 homodimer. Top: snapshots from the simulations. Middle: plots of the surface area buried within the dimer interface (counting the contributions from domains I, II, and III) as a function of simulation time (for EGFR--Her2 \[−EGF\] and Her2--Her2, results of two independent simulations are shown). Bottom: schematics illustrating the conformation of domain II and the dimer interface. Conformations of the bent and straight domain II are highlighted by the black lines, and the gap in the dimer interface is indicated by a V-shaped outline when present. For clarity, domain IV is not shown.**DOI:** [http://dx.doi.org/10.7554/eLife.00708.006](10.7554/eLife.00708.006)Video 1.The simulation of the ligand-free EGFR--Her2 ectodomain heterodimer with Her2 colored red and EGFR blue. A gap between the N-terminal portion of each subunit's domain II develops during the simulation.**DOI:** [http://dx.doi.org/10.7554/eLife.00708.007](10.7554/eLife.00708.007)10.7554/eLife.00708.007

In terms of their location and potential impact on dimer stability, the gaps observed in our simulations are reminiscent of the one in the crystal structure of ligand-free dEGFR dimer ([@bib1], [@bib2]). The dEGFR gap results in a reduced dimer interface area of ∼2300 Å^2^, compared to ∼3400 Å^2^ in the 1- and 2-ligand dEGFR dimers, where the gap is closed ([Figure 2](#fig2){ref-type="fig"}). This reduction of the dimer interface area is believed to account for the relatively weak dimerization affinity of the ligand-free dEGFR, which is ∼30 times lower than that of ligand-bound dEGFR. [Figure 4](#fig4){ref-type="fig"} shows that the reduction of the dimer interface is similarly observed in our simulations of the ligand-free EGFR--Her2 heterodimer and Her2 homodimer: when the gap is wide open, the surface area buried within the interface is ∼2600 Å^2^, compared to ∼3500 Å^2^ in the ligand-bound heterodimer. We thus suggest that the same structural mechanism that weakens ligand-free dEGFR homodimers ([@bib1], [@bib2]) also disfavors ligand-free EGFR--Her2 dimerization and Her2 homodimerization. On the other hand, ligand binding in the EGFR subunit helps to keep domain II straight, which prevents the opening of the gap and stabilizes the dimer interface of EGFR--Her2 heterodimer ([Figure 4](#fig4){ref-type="fig"}). This is reminiscent of the recent finding ([@bib30]) that one bound ligand is sufficient to activate an EGFR dimer.

Her3--Her2 heterodimer {#s2-4}
----------------------

Among the dimerization partners of Her2, Her3 is particularly notable in that the Her3--Her2 heterodimers are potent signaling units, and in that the normal and pathogenic signaling through Her2 and Her3 relies strongly on Her3--Her2 dimerization ([@bib4]; [@bib27]). We thus studied the Her3--Her2 heterodimer in ways similar to our study of EGFR--Her2 heterodimers and the Her2 homodimer. We first modeled the Her3--Her2 heterodimer using the resolved crystal structure of the Her3 monomer ([@bib7]) and our model of the EGFR--Her2 heterodimer as templates ('Materials and methods'). The EGF-like domain of the Her3 ligand heregulin-alpha (HRG) was then introduced into the Her3 binding site between domains I and III, in accordance with the pose of EGFR-bound EGF.

The resulting model of the Her3--Her2 heterodimer was then simulated, first with HRG bound, in which case the dimer interface remained stable ([Figure 5A](#fig5){ref-type="fig"}). After ∼4 µs of simulation the ligand was removed, and the resulting ligand-free heterodimer was then simulated again. Without the ligand, the Her3 subunit underwent conformational changes similar to those described above for the ligand-free EGFR subunit, including a bending of domain II. As a result, a gap again emerged in the dimer interface. In the first series of simulations the gap in the Her3--Her2 heterodimer was often partially closed, but re-opened repeatedly and resulted in a significant decrease in the buried surface area in the dimer interface. In the second series, the gap was steadily open once the ligand was removed ([Figure 5B](#fig5){ref-type="fig"}). These observations suggest that Her3--Her2 heterodimerization, similar to that of EGFR--Her2, is promoted by the stabilization of the dimer interface following ligand binding.10.7554/eLife.00708.008Figure 5.Her3--Her2 heterodimer.(**A**) Snapshots from the simulations of the Her3--Her2 heterodimer with (left) and without (right) HRG bound to Her3. At the end of the simulation with HRG bound to Her3, HRG was removed, and the resulting system was resolvated and further simulated without the ligand. A gap opened in the dimer interface, as illustrated by the snapshot on the right. For clarity, these images omit domain IV. (**B**) The surface area buried within the dimer interface, counting the contributions only from domains I, II, and III, plotted as a function of time. Two independent sets of two simulations each (with and without HRG) are shown.**DOI:** [http://dx.doi.org/10.7554/eLife.00708.008](10.7554/eLife.00708.008)

Atomic detail of the dimer interfaces in the asymmetric dimers {#s2-5}
--------------------------------------------------------------

Our simulations suggest that ligand binding promotes the formation of asymmetric dEGFR or EGFR-family dimers by allowing specific favorable interactions between the domain II N-terminal regions of the two subunits. We found that the asymmetric dimers we examined---the EGFR--Her2 and Her3--Her2 heterodimers, the 1-ligand EGFR homodimer, and the 1- and 2-ligand dEGFR homodimers---all shared certain key atomic-level interactions between subunits. In particular, hydrogen bonds between Gln194 (in EGFR or Her3 numbering) of the ligand-bound subunit and Cys213 and His215 (in Her2 numbering; [Figure 6A](#fig6){ref-type="fig"}) of the ligand-free subunit ([Figure 6B](#fig6){ref-type="fig"}) were particularly stable. The presence of these hydrogen bonds is consistent with the reported crystal structures of the dEGFR asymmetric dimers after a 180° χ~2~ rotamer flip at the histidine (which would presumably be consistent with the same electron density). In contrast, these hydrogen bonds are not present in the crystal structure or in simulations of the symmetric 2-ligand EGFR dimer, and they are precluded by the gap in the dimer interface of all ligand-free dimers we examined (including the ligand-free dEGFR crystal structure and our simulations of ligand-free EGFR and Her2 homodimers and EGFR--Her2 heterodimers). Our observations suggest an important role for Gln194 of the ligand-bound subunit in stabilizing 1-ligand dimers. Notably, the glutamine residue is conserved in EGFR, Her3, Her4, and dEGFR, which bind ligands, but not in Her2 ([Figure 6A](#fig6){ref-type="fig"}), which does not. Mutating Gln194 in EGFR and Her3 may thus hinder their heterodimerization with Her2, and mutating the corresponding residue (Gln189) in dEGFR may hinder its homodimerization.10.7554/eLife.00708.009Figure 6.Details of the dimer interfaces in Her2 heterodimers.(**A**) The sequence alignments of EGFR, Her2, Her3, and dEGFR for the part of domain II corresponding to EGFR residues 167--286. Three sets of residues (green, red, and blue, respectively), which are involved in three sets of important interactions at the dimer interface, are highlighted. (**B**) Top: the role of EGFR residue Gln194 in the EGFR--Her2 dimer interface. Hydrogen bonds and salt bridges are indicated by red dashed lines. Bottom: the distances between the key atoms involved in these hydrogen bonds are shown as functions of time. (**C**) Left: superimposition of 1-ligand EGFR homodimer and 1-ligand EGFR--Her2 heterodimer, with dimerization arms highlighted by the red box. Middle and right: Her2's dimerization arm in the EGFR--Her2 heterodimer is conformationally less stable than the dimerization arm of the ligand-free subunit of the 1-ligand EGFR homodimer, likely because the Tyr251--Arg285 cation--π interaction is only present in the latter dimer. Dark blue is used for the EGFR dimerization arm in the EGFR homodimer, and dark gray for the EGFR dimerization arm in the EGFR--Her2 heterodimer.**DOI:** [http://dx.doi.org/10.7554/eLife.00708.009](10.7554/eLife.00708.009)

Certain inter-subunit interactions appeared to be unique to Her2 heterodimers. In particular, Arg228 of EGFR interacted stably with Glu243 of Her2 through a salt bridge in our simulations of the ligand-bound EGFR--Her2 heterodimer ([Figure 6B](#fig6){ref-type="fig"}). Similarly, Arg228 of Her3 interacted stably with the same glutamate through a water bridge in our simulations of the Her3--Her2 heterodimer. Although this arginine is present in both EGFR and Her3, it is not present in Her2, Her4, or dEGFR. Notably, EGFR and Her3 are the two common dimerization partners of Her2 in the EGFR family, and only Her2 bears a negatively charged residue at the position of the Glu243 ([Figure 6A](#fig6){ref-type="fig"}). This is consistent with the notion that Her2 has been fine-tuned for heterodimerization with EGFR and Her3.

Experimentally, heterodimerization between Her2 and ligand-bound EGFR or Her3 ectodomains is much weaker than homodimerization of EGFR, Her4, or dEGFR ectodomains ([@bib21]; [@bib16]). Our simulations suggest that this difference in stability may be due to unique conformational dynamics in the dimerization arm of Her2. The dimerization arm plays a key role in maintaining dimer stability, and dimerization arm-mediated interactions are very similar in crystal structures of dEGFR and human EGFR dimers ([@bib2]). In our simulations, however, the dimerization arm of Her2 in the EGFR--Her2 dimer deviated significantly from its initial conformation in the course of the simulation, whereas the dimerization arms of EGFR and dEGFR in homodimers did not ([Figure 6C](#fig6){ref-type="fig"}). A cation--π interaction at the tip of the dimerization arm in the 1-ligand EGFR dimer between Tyr251 and Arg285 of the unliganded subunit ([Figure 6C](#fig6){ref-type="fig"}) appears to be particularly important in stabilizing the dimer. The residue at the position of Tyr251 is conserved as tyrosine or phenylalanine in dEGFR and all members of the human EGFR family. The residue at the position of Arg285 is conserved as arginine, except in Her2, where it is replaced by leucine (Leu291; [Figure 6A](#fig6){ref-type="fig"}). It is tempting to suggest that this missing arginine in Her2 may explain its weak ectodomain heterodimerization compared to the homodimerization of dEGFR, EGFR, and Her4, and that an L291R mutation in Her2 may promote Her2 heterodimerization and facilitate the crystallization of a Her3--Her2 or EGFR--Her2 dimer.

Discussion {#s3}
==========

Given the implication of Her2 in disease and its central role in mediating cell signaling, elucidation of the molecular mechanisms regulating Her2 activation is of great importance. The long-timescale MD simulations reported here support the notion of a simple and evolutionarily conserved structural mechanism controls homo- and heterodimerization of Her2, and thereby Her2 activation. Our simulations revealed inherent instability in the dimer interfaces of the ligand-free EGFR--Her2 and Her3--Her2 heterodimers and the Her2 homodimer, and indicated that the binding of a single ligand is sufficient to stabilize the heterodimer interfaces. These observations complement the crystallographic analysis, shedding further light on the structural mechanism underlying the preference of Her2 to partner with a ligand-bound EGFR or Her3, rather than with Her2 or ligand-free EGFR or Her3 ([@bib27]; [@bib20]; [@bib33]).

Our simulations showed the conformation of domain II, which is determined by ligand binding, to be critical to the stability of the dimer interface. A ligand bound to EGFR (or to another member of the family) acts as a wedge that pushes domains I and III apart, straightening the otherwise bent domain II ([@bib1]). (Domain II is bent in the crystal structures of ligand-free EGFR, Her2, Her3, Her4, and dEGFR.) We simulated the transition from the straight to the bent conformation of domain II upon removal of the bound ligand in EGFR and Her3 and the consequent development of the gap in the dimer interface. Our simulations suggest that, for the gap to open, both domain IIs of the two subunits in a dimer need to adopt a bent conformation.

One feature unique to the dimerization and activation of receptors of the EGFR family (Her2 included), but not to other families of receptor tyrosine kinases ([@bib28]), is that the dimer interface is mediated by the receptors and does not involve any direct contribution from the bound ligands. Instead of directly participating in the dimerization, a bound ligand regulates the conformation of domain II and potentiates it for dimerization. In this context, it is not surprising that the seemingly minor effect of ligand binding on the conformation of domain II in the heterodimerization partners of Her2 demonstrated by our simulations is of great importance to the regulation of Her2 activity. Our consistent observation of the gap that disrupts the dimer interfaces in the ligand-free EGFR--Her2 and Her3--Her2 heterodimers, and in Her2 and dEGFR homodimers, as well as the fact that domain II is bent in crystal structures of ligand-free EGFR, Her2, Her3, Her4, and dEGFR, suggests that the structural mechanism for the control of dimerization has been preserved from *Drosophila* to the human EGFR family.

Materials and methods {#s4}
=====================

Modeling of dimers {#s4-1}
------------------

Because EGFR, Her2, and Her3 are closely related phylogenetically and share a high degree of sequence identity, we used the EGFR ectodomain homodimer as a structural template for the modeling of the Her2 ectodomain homodimer and the EGFR--Her2 and Her3--Her2 ectodomain heterodimers. The sequence identity between the ectodomains of EGFR and Her2 is 40%, while that between the ectodomains of EGFR and Her3 is 41%. In the structural alignments for the modeling, we used the region corresponding to EGFR residues 240--309, since this is the part of domain II that appears to be essential for dimerization ([@bib12]), and since in our simulations of EGFR the N-terminal portion of domain II exhibited bending around the hinge situated approximately at residue 240 ([Figure 3](#fig3){ref-type="fig"}). In this region, sequence identity to EGFR is 50% and 46% for Her2 and Her3, respectively ([Figure 6A](#fig6){ref-type="fig"}).

The Her2 subunit of the EGFR--Her2 heterodimer was modeled based on the Her2 monomer crystal structure from PDB entry 3BE1 ([@bib6]), and missing residues in domains I--III were filled from PDB entries 1S78 ([@bib17]) and 2A91 ([@bib19]). The Her2 monomer was aligned with the ligand-free EGFR subunit from the 1-ligand EGFR dimer using EGFR residues 240--309 (and the corresponding residues of Her2) for reference. The part of domain IV of Her2 that is missing in the crystal structures (beyond residue 608) was modeled based on the EGFR structure. The minor clashes between Her2 and EGFR in the original model were resolved by adjusting the side chains of the amino acids involved. To obtain the Her2 homodimer, the Her2 monomer was used to replace the EGFR subunit in the ligand-free EGFR--Her2 heterodimer.

The Her3--Her2 heterodimer was modeled based on our model of the EGFR--Her2 dimer taken at *t* = 0 (i.e., before simulation). Individual domains from the crystal structure of the tethered Her3 ectodomain (PDB entry 1M6B \[[@bib7]\]) were aligned on the respective domains of the EGFR template. Because domain II is straight in the EGFR template and bent in the Her3 crystal structure, the alignment was carried out in three separate steps. Specifically, Her3 residues 166--188, 189--238, and 239--307 were separately aligned with their EGFR counterparts. The residues at the borders between the parts of Her3 that were aligned as rigid bodies were then adjusted to ensure appropriate connectivity; a few minor clashes between the domains of Her3 and between Her3 and Her2 were eliminated by adjusting amino acid side chains. HRG was taken from PDB entry 1HAE ([@bib24]) and aligned with the EGF bound to the EGFR template, using EGF's residues 26--46 for reference (as this part appears to be most similar structurally between the two).

Domains IVs of receptors of the EGFR family are generally more flexible than the other ectodomains and are commonly unresolved in crystal structures. Thus, structural analysis of domain IVs starting from homology models may be particularly challenging. Although domain IVs were included in our models and simulations, they were not a main concern of this study.

Simulation details {#s4-2}
------------------

The simulations were performed on the special-purpose supercomputer, Anton ([@bib39]), using the CHARMM22\* force field ([@bib32]; [@bib35]) for proteins and TIP3P ([@bib25]) as the water model. The simulated systems were solvated in water with NaCl (Na^+^ ions were first added to neutralize the net charge of the system, and then equal numbers of Na^+^ and Cl^−^ were added so that the concentration of Na^+^ reached 0.15 M), with residues set to their dominant protonation states at pH 7. As an equilibration stage, the protein backbone atoms were first restrained to their initial positions, using a harmonic potential with a force constant of 1 kcal mol^−1^ Å^−2^. The force constant was linearly scaled down to zero over 50 ns. Simulations were performed in the NPT ensemble for the equilibration step and in the NVT ensemble afterwards, with T = 310 K, p=1 bar, and Berendsen's coupling scheme ([@bib5]) with one temperature group. Water molecules and all bond lengths to hydrogen atoms were constrained using M-SHAKE ([@bib26]). Van der Waals and short-range electrostatic interactions were cut off at 12.5 Å. Long-range electrostatic interactions were calculated using the *k*-space Gaussian split Ewald method ([@bib38]) with a 64 × 64 × 64 mesh. The simulation time step was 1 fs for the equilibration stage and 2.5 fs for production simulations; the r-RESPA integration method was used with long-range electrostatics evaluated every 5 fs ([@bib41]).

The simulated systems included the EGFR ectodomain dimers with two EGF ligands (three simulations) or one ligand (also three simulations); 1-ligand EGFR--Her2 ectodomain heterodimer (one simulation), ligand-free heterodimer (two simulations), Her2 homodimer (two simulations), 1-ligand Her3--Her2 heterodimer (two simulations), and ligand-free Her3--Her2 heterodimer (two simulations); and ligand-free dEGFR dimer (two simulations starting from the 2-ligand crystal structure and one from the ligand-free crystal structure). The size of the simulated systems was ∼270,000 atoms, in a periodic box of approximately 140 × 140 × 140 Å^3^. Modeling, analysis, and visualization were performed using VMD ([@bib22]). The data for buried area shown in the figures was averaged over a 200-ns window.

Repeated simulations of a given system produced largely similar results. In both simulations of the ligand-free EGFR--Her2 dimer, for example, a gap consistently developed at the dimer interface ([Figure 4B](#fig4){ref-type="fig"}). Three simulations of the 1-ligand EGFR homodimer ([Figure 3D](#fig3){ref-type="fig"}), generated average structures with a root-mean-squared deviation of 1.9--4.8 Å from one another, as measured based on the Cα atoms of domains I--III. By the same measurement, the two crystal structures of the 2-ligand EGFR homodimer (PDB entries 1IVO and 1MOX) differ from one other by 4.0 Å.

We thank John Kuriyan, Michael Eastwood, and Stefano Piana for helpful discussions, Ansgar Philippsen for assistance with graphics, and Mollie Kirk and Berkman Frank for editorial assistance. We also thank the reviewers for their helpful suggestions.
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Thank you for sending your work entitled "Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family" for consideration at *eLife*. Your article has been favorably evaluated by a Senior Editor and 3 reviewers, one of whom, Axel Brunger, is a member of our Board of Reviewing Editors.

The Reviewing editor and the other reviewers discussed their comments before we reached this decision, and the Reviewing editor has assembled the following comments to help you prepare a revised submission.

General assessment:

The mechanism of Her2 activation and signaling is of considerable importance considering its role in human disease (including cancer) and as a drug target. The available biochemical data suggest that the activation process upon ligand binding requires formation of a heterodimer consisting of Her2 and Her3. Her2 lacks ligand binding (or binding is weak), whereas Her3 does not have significant kinase activity. Thus, it is only upon hetero-dimerization that ligand binding can initiate kinase activity. Yet, structural studies by x-ray crystallography of the human EGFR-family receptors ectodomains showed only symmetric dimers with ligands bound in both monomers. Intriguingly, crystal structures of *Drosophila* EGFR ectodomains showed asymmetric dimers with only one ligand bound. The question, however, was if the *Drosophila* crystal structures are representative, what is going on for the human EGFR receptors as well. This work now suggests that this is indeed the case: starting from the crystal structures of the human Her2 homodimer as well as the Her2-Her3 heterodimer, long-timescale (microsecond) molecular dynamics simulations were performed. The simulations were first successfully tested starting from the *Drosophila* heterodimer structures.

Highlight:

The simulations show that a model of the human Her2 homodimer is not stable, but, rather, that the dimer interface opens to produce a large gap. In contrast, a model of the Her2-Her3 heterodimer with one bound ligand was stable. This work thus suggests that the asymmetric *Drosophila* EGFR ectodomain crystal structures indeed represent the norm, rather than the exception.

While this is an important finding, the simulations should allow the authors to draw some mechanistic conclusions about how the conformational changes within the various dimers occur and how the different interfaces are stabilized. Such additional mechanistic insights would also illustrate the power of their long-time simulations and considerably strengthen this work.

Required revisions:

1\) By taking the richness of the MD simulations and reducing them to cartoons in [Figures 3A, 4, and 5](#fig3 fig4 fig5){ref-type="fig"}, the authors do not go much beyond simply confirming conclusions already drawn from the studies of *Drosophila* EGFR. Surely the purpose of simulations such as those described here is to generate informative models that make experimentally testable predictions? In the crystallographic studies of dEGFR, identification of residues involved in interactions across the asymmetric dimer interface was informative. The nature of this new interface is crucial for understanding the fly receptor, but here the authors unfortunately give no details for the analogous interfaces in the human heterodimers studied. This omission deprives those in this field of the most useful information to be gleaned from the simulations presented. Are the interfaces (e.g., at the top of [Figure 4A](#fig4){ref-type="fig"}) similar to those seen in dEGFR? Do they involve conserved residues?

2\) The "structural explanation for the preference of Her2 to partner with a ligand-bound EGFR or Her3, rather than with Her2 or ligand-free EGFR or Her3" is not really a result of this paper. Quite frankly, this was already clear from the *Drosophila* work. What the present (excellent) study does add to this, though, is the potential of a detailed view -- yet the authors disappointingly describe no details that can be used for designing experiments. The brief discussion does not suffice and key areas of contact are omitted from [Figure 6B](#fig6){ref-type="fig"}. Are there key residues in the domain II interface in the asymmetric hEGFR dimer (outside the region shown in [Figure 6B](#fig6){ref-type="fig"}) that are well conserved? Can predictions be made for mutations that might selectively destabilize the asymmetric hEGFR dimer but not the symmetric 2-ligand dimer? These would be useful outcomes of the modeling studies and analysis of these questions are likely to yield valuable insight in and of itself.

3\) Why are heterodimers formed between the EGFR and Her2 (or Her2 and Her3) ectodomains so much weaker than EGFR-EGFR ectodomain homodimers? This is a clear experimental result in the literature. In fact, EGFR-Her2 ectodomain heterodimers have not yet been directly observed, following ligand binding, although there are hints from biophysical studies that weak Her2-Her3 ectdomain dimers may form (this varies from study to study). By contrast, EGFR and dEGFR ectodomain dimers are strong (at least 50-fold stronger). The simulations might address the question of different dimerization strengths. By ignoring the well-established affinity differences -- when taken at face value -- the presentation in this work is a little misleading. For example, what do the authors mean by suggesting that the Her3-Her2 heterodimers are particularly robust? If they mean that the affinity of Her3 for Her2 is particularly strong, they are not correct -- there is no evidence for this. Evidence for heterodimer formation is qualitative at best, and the only quantitative data show that EGFR-EGFR homodimers and Her4-Her4 homodimers are much "tighter" than any homodimer, at least where ectodomains are concerned. Analysis and description of the dimer interfaces could provide insight into this issue too.

4\) Although this manuscript is well-written and beautifully illustrated, it is spoiled by its logical framework. For example, [Figure 1B](#fig1){ref-type="fig"} shows the symmetrical human EGFR (hEGFR) dimer. It also shows tethered and untethered forms of the monomer, but specifically does not address them. If these are not addressed, why illustrate them. The fact that Her2 without a ligand looks superficially like hEGFR with a ligand makes one want to assume that this is how Her2 works. Also, it should be made clearer (e.g., in the figure caption) which specific crystal structures of which domains and homo or heterodimers have been determined, along with their PDB IDs.

5\) [Figure 2A](#fig2){ref-type="fig"} shows the symmetric *Drosophila* EGFR (dEGFR) dimer, the logical counter-part of the symmetric human EGFR dimer in [Figure 1](#fig1){ref-type="fig"}. It also shows the effect of a simulation on dEGFR without both its ligands. [Figure 3](#fig3){ref-type="fig"} shows a simulation of hEGFR without one its ligands. It seems that both the human and *Drosophila* x-ray structures should be introduced together so as to emphasize their different symmetries.

6\) The results of parallel simulations in both hEGFR and dEGFR need to be shown. This may require additional work as hEGFR has been simulated without one ligand whereas dEGFR has been simulated without both ligands.

7\) The results of the MD simulations seem reproducible in that two independent several-micro-second simulations give similar results for this huge system with almost 300,000 atoms. This remarkable result could be emphasized more explicitly by comparison of the final structures of the respective pairs of simulations.
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Author response

*The simulations show that a model of the human Her2 homodimer is not stable, but, rather, that the dimer interface opens to produce a large gap. In contrast, a model of the Her2-Her3 heterodimer with one bound ligand was stable. This work thus suggests that the asymmetric Drosophila EGFR ectodomain crystal structures indeed represent the norm, rather than the exception*.

*While this is an important finding, the simulations should allow the authors to draw some mechanistic conclusions about how the conformational changes within the various dimers occur and how the different interfaces are stabilized. Such additional mechanistic insights would also illustrate the power of their long-time simulations and considerably strengthen this work*.

We thank the reviewers for these comments. In the revised manuscript, we have dedicated an updated figure ([Figure 6](#fig6){ref-type="fig"}) and a new sub-section of the Results to highlight the residue--residue interactions that are key to the stability of these asymmetric EGFR family dimers. We have also added suggestions for mutations that may enhance the stability of these asymmetric dimers and potentially facilitate their crystallization.

*Required revisions*:

*1) By taking the richness of the MD simulations and reducing them to cartoons in [Figures 3A, 4, and 5](#fig3 fig4 fig5){ref-type="fig"}, the authors do not go much beyond simply confirming conclusions already drawn from the studies of* Drosophila *EGFR. Surely the purpose of simulations such as those described here is to generate informative models that make experimentally testable predictions? In the crystallographic studies of dEGFR, identification of residues involved in interactions across the asymmetric dimer interface was informative. The nature of this new interface is crucial for understanding the fly receptor, but here the authors unfortunately give no details for the analogous interfaces in the human heterodimers studied. This omission deprives those in this field of the most useful information to be gleaned from the simulations presented. Are the interfaces (e.g., at the top of [Figure 4A](#fig4){ref-type="fig"}) similar to those seen in dEGFR? Do they involve conserved residues*?

In the revised manuscript, we provide further details of the dimer interfaces observed in our MD simulations. In particular, we report residue-specific details of the interfaces of asymmetric EGFR family dimers in the new sub-section of the Results and the new version of [Figure 6](#fig6){ref-type="fig"}. Based on the conformational dynamics of the dimer interfaces, we determined that the interactions of Gln194 (EGFR numbering) with Cys213 and His215 (Her2 numbering), which are stable in our simulations of the 1-ligand EGFR homodimer and the Her2 heterodimers with ligand-bound EGFR or Her3, are critical to the stability of these asymmetric dimers. These interactions are also formed in the crystal structures of the asymmetric dEGFR dimers. We have added a discussion of these interactions, and of the conservation of the residues involved, to the revised manuscript.

*2) The "structural explanation for the preference of Her2 to partner with a ligand-bound EGFR or Her3, rather than with Her2 or ligand-free EGFR or Her3" is not really a result of this paper. Quite frankly, this was already clear from the* Drosophila *work. What the present (excellent) study does add to this, though, is the potential of a detailed view -- yet the authors disappointingly describe no details that can be used for designing experiments. The brief discussion does not suffice and key areas of contact are omitted from [Figure 6B](#fig6){ref-type="fig"}. Are there key residues in the domain II interface in the asymmetric hEGFR dimer (outside the region shown in [Figure 6B](#fig6){ref-type="fig"}) that are well conserved? Can predictions be made for mutations that might selectively destabilize the asymmetric hEGFR dimer but not the symmetric 2-ligand dimer? These would be useful outcomes of the modeling studies and analysis of these questions are likely to yield valuable insight in and of itself*.

We agree that the overall structural mechanism of Her2 dimerization may largely be inferred from the structures of the dEGFR dimers, and that much of the value of our work lies in its potential to provide a detailed view of the relevant dimer interfaces. As the reviewers suggested, we have thus revised the manuscript to place more emphasis on the atomic details of our Her2 heterodimer models, with a particular focus on the dimer interfaces. We have also revised the relevant high-level statements in the manuscript to reflect this understanding. The new version of [Figure 6](#fig6){ref-type="fig"} presents important details of the interactions between the N-terminal regions of the domain IIs in the asymmetric dimers, in addition to the interactions around the "dimerization arms". Because the interactions centered on Gln194 (EGFR numbering) are stable in the asymmetric EGFR family dimers but not in their symmetric counterparts, we suggest in the revised manuscript that mutation of this residue would destabilize the former more than the latter dimers. Additionally, we have now highlighted the salt bridge between Arg228 (EGFR numbering) and Glu243 (Her2 numbering), which is likely important to the stability of the Her2 dimers. In the revised manuscript we further suggest that mutating Arg228 may hinder the heterodimerization of EGFR and Her3 with Her2, but not the homodimerization.

*3) Why are heterodimers formed between the EGFR and Her2 (or Her2 and Her3) ectodomains so much weaker than EGFR-EGFR ectodomain homodimers? This is a clear experimental result in the literature. In fact, EGFR-Her2 ectodomain heterodimers have not yet been directly observed, following ligand binding, although there are hints from biophysical studies that weak Her2-Her3 ectdomain dimers may form (this varies from study to study). By contrast, EGFR and dEGFR ectodomain dimers are strong (at least 50-fold stronger). The simulations might address the question of different dimerization strengths. By ignoring the well-established affinity differences -- when taken at face value -- the presentation in this work is a little misleading. For example, what do the authors mean by suggesting that the Her3-Her2 heterodimers are particularly robust? If they mean that the affinity of Her3 for Her2 is particularly strong, they are not correct -- there is no evidence for this. Evidence for heterodimer formation is qualitative at best, and the only quantitative data show that EGFR-EGFR homodimers and Her4-Her4 homodimers are much "tighter" than any homodimer, at least where ectodomains are concerned. Analysis and description of the dimer interfaces could provide insight into this issue too*.

The reviewers are correct that there is no evidence indicating that the affinity of Her3 for Her2 is particularly strong. We have revised the sentence of the original manuscript that appeared to suggest otherwise, and we have clarified the point we intended to convey, which was the functional importance of full-length Her3--Her2 heterodimers.

In the revised manuscript, we have also attempted to address the reviewers' question of why ectodomain heterodimerization of Her2 and Her3 is weaker than ectodomain homodimerization of dEGFR, EGFR, and Her4. To elucidate the structural basis for the different dimerization strengths, we re-examined the interactions at the dimerization interfaces. In the revised manuscript, we now identify variance at key residues that may explain the strength of dEGFR and human EGFR homodimers relative to Her2 heterodimers. Specifically, we suggest that a cation--π interaction between Tyr251 and Arg285 (EGFR numbering) in the homodimers may be key to the stabilization of the dimerization arms in the dimer interfaces. Furthermore, we suggest that the replacement of the arginine in Her2 by a leucine, which distinguishes it from dEGFR and the other members of the EGFR family, may explain the weak ectodomain heterodimerization of Her2 ectodomains relative to the homodimerization of dEGFR and human EGFR ectodomains. We further speculate that the L291R Her2 mutation, which may stabilize Her2 heterodimers with EGFR and Her3, may facilitate crystallization of Her2--Her3 and Her2--EGFR dimers.

*4) Although this manuscript is well-written and beautifully illustrated, it is spoiled by its logical framework. For example, [Figure 1B](#fig1){ref-type="fig"} shows the symmetrical human EGFR (hEGFR) dimer. It also shows tethered and untethered forms of the monomer, but specifically does not address them. If these are not addressed, why illustrate them. The fact that Her2 without a ligand looks superficially like hEGFR with a ligand make one want to assume that this is how Her2 works. Also, it should be made clearer (e.g., in the figure caption) which specific crystal structures of which domains and homo or heterodimers have been determined, along with their PDB IDs*.

As suggested, we have removed the tethered conformation from the figures and specified which crystal structures the cartoon diagrams represent by including their PDB IDs. We have also attempted to improve the manuscript's logical framework by presenting the dEGFR dimer together with the symmetric EGFR dimer in the revised [Figure 1](#fig1){ref-type="fig"}, as described below in our response to reviewer comment 5.

*5) [Figure 2A](#fig2){ref-type="fig"} shows the symmetric* Drosophila *EGFR (dEGFR) dimer, the logical counter-part of the symmetric human EGFR dimer in [Figure 1](#fig1){ref-type="fig"}. It also shows the effect of a simulation on dEGFR without both its ligands. [Figure 3](#fig3){ref-type="fig"} shows a simulation of hEGFR without one its ligands. It seems that both the human and* Drosophila *x-ray structures should be introduced together so as to emphasize their different symmetries*.

In the revised manuscript, the 2-ligand asymmetric dEGFR dimer is now juxtaposed with the symmetric EGFR dimer in [Figure 1](#fig1){ref-type="fig"} to emphasize their different symmetries. We have also revised the text so that the two dimers are introduced together.

*6) The results of parallel simulations in both hEGFR and dEGFR need to be shown. This may require additional work as hEGFR has been simulated without one ligand whereas dEGFR has been simulated without both ligands*.

In the revised manuscript we now report parallel simulations of the ligand-free EGFR dimer and show that a gap develops at the dimer interface, as we had previously observed for the ligand-free dEGFR dimer ([Figure 4B](#fig4){ref-type="fig"}).

*7) The results of the MD simulations seem reproducible in that two independent several- micro-second simulations give similar results for this huge system with almost 300,000 atoms. This remarkable result could be emphasized more explicitly by comparison of the final structures of the respective pairs of simulations*.

We agree that the reproducibility of our simulations warrants a more explicit discussion. At the end of the Methods section in the revised manuscript, we now report that the average structures observed in three simulations of the 1-ligand EGFR homodimer differ by 1.9--4.8 Å in terms of the RMSD of the Cα atoms, which is comparable to the Cα RMSD between the two available crystal structures of the 2-ligand EGFR dimer (4.0 Å). This comparison differs only slightly from the one the reviewers suggested in that the average, rather than the final, conformation of each simulation is used, in light of the fact that the average conformation of a simulation generally represents the ensemble of conformations sampled by the simulation better than the final one.
